BRPI0518359A2 - antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc - Google Patents

antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc

Info

Publication number
BRPI0518359A2
BRPI0518359A2 BRPI0518359-6A BRPI0518359A BRPI0518359A2 BR PI0518359 A2 BRPI0518359 A2 BR PI0518359A2 BR PI0518359 A BRPI0518359 A BR PI0518359A BR PI0518359 A2 BRPI0518359 A2 BR PI0518359A2
Authority
BR
Brazil
Prior art keywords
gaba
treatment
receptor
steroid
antagonists
Prior art date
Application number
BRPI0518359-6A
Other languages
English (en)
Inventor
Torbjoern Baeckstroem
Lundgren Per
Ming-De Wang
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of BRPI0518359A2 publication Critical patent/BRPI0518359A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ANTAGONISTAS DE GABA-ESTERàIDE E SEU USO PARA O TRATAMENTO DE DISTéRBIOS DO SNC. A invenção refere-se a compostos exibindo ação de bloqueio de 3-alfa-hidroxi-5-alfa/beta-esteróide sem ou com apenas baixo antagonismo contra o receptor (GABA-A) do ácido gama-aminobutírico (A), e são apresentados compostos exibindo antagonismo parcial contra o dito receptor. São sugeridos métodos para a prevenção, tratamento e/ou alívio de vários distúrbios do SNC, bem como composições farmacêuticas para tal uso.
BRPI0518359-6A 2004-11-18 2005-11-07 antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc BRPI0518359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62951104P 2004-11-18 2004-11-18
PCT/SE2005/001671 WO2006054938A1 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
BRPI0518359A2 true BRPI0518359A2 (pt) 2008-11-18

Family

ID=36407411

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518359-6A BRPI0518359A2 (pt) 2004-11-18 2005-11-07 antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc

Country Status (11)

Country Link
US (2) US8114860B2 (pt)
EP (1) EP1812009B1 (pt)
JP (1) JP4914368B2 (pt)
CN (1) CN101076340B (pt)
AU (1) AU2005307151B2 (pt)
BR (1) BRPI0518359A2 (pt)
CA (1) CA2585359C (pt)
DK (1) DK1812009T3 (pt)
ES (1) ES2423493T3 (pt)
MX (1) MX2007006032A (pt)
WO (1) WO2006054938A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2423493T3 (es) 2004-11-18 2013-09-20 Umecrine Ab Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC
IN2014DN02014A (pt) 2006-11-21 2015-07-10 Umecrine Ab
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
CA2786330C (en) 2010-01-14 2013-11-19 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614499A (en) * 1985-04-29 1986-09-30 Universite Laval Simulator for use as a neurosurgical aid in determining potential paths for the implantation of probes through the human body
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US20030125311A1 (en) * 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
ES2423493T3 (es) 2004-11-18 2013-09-20 Umecrine Ab Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC

Also Published As

Publication number Publication date
ES2423493T3 (es) 2013-09-20
DK1812009T3 (da) 2013-08-05
EP1812009A1 (en) 2007-08-01
MX2007006032A (es) 2007-10-17
CA2585359C (en) 2013-01-08
US8114860B2 (en) 2012-02-14
EP1812009B1 (en) 2013-05-15
CN101076340A (zh) 2007-11-21
US8372824B2 (en) 2013-02-12
US20120142657A1 (en) 2012-06-07
WO2006054938A1 (en) 2006-05-26
AU2005307151A1 (en) 2006-05-26
CA2585359A1 (en) 2006-05-26
JP2008525317A (ja) 2008-07-17
JP4914368B2 (ja) 2012-04-11
US20080070876A1 (en) 2008-03-20
CN101076340B (zh) 2011-01-12
AU2005307151B2 (en) 2011-10-20
EP1812009A4 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
GB0625648D0 (en) Compounds
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
WO2006135627A3 (en) Inhibitors of akt activity
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EP2350129A4 (en) PD1 Antagonist Compositions and Methods for their Use
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.